Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jin Medical International (ZJYL) Cash & Equivalents (2022 - 2025)

Jin Medical International's Cash & Equivalents history spans 4 years, with the latest figure at $7.5 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 8.29% year-over-year to $7.5 million; the TTM value through Sep 2025 reached $7.5 million, down 8.29%, while the annual FY2025 figure was $7.5 million, 8.29% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $7.5 million at Jin Medical International, down from $8.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $8.1 million in Q3 2024 and bottomed at $4.8 million in Q3 2022.
  • The 4-year median for Cash & Equivalents is $7.2 million (2023), against an average of $6.8 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 44.59% in 2023 before it dropped 8.29% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $4.8 million in 2022, then surged by 44.59% to $6.9 million in 2023, then rose by 17.41% to $8.1 million in 2024, then decreased by 8.29% to $7.5 million in 2025.
  • Per Business Quant, the three most recent readings for ZJYL's Cash & Equivalents are $7.5 million (Q3 2025), $8.1 million (Q3 2024), and $6.9 million (Q3 2023).